• OPEN AN ACCOUNT
Indian Indices
Nifty
24,426.85 -74.05
(-0.30%)
Sensex
79,809.65 -270.92
( -0.34%)
Bank Nifty
53,655.65 -164.70
( -0.31%)
Nifty IT
35,181.25 -307.50
( -0.87%)
Global Indices
Nasdaq
45,566.70 -91.21
(-0.20%)
Dow Jones
6,481.27 -41.59
(-0.64%)
Hang Seng
42,764.54 -64.25
(-0.15%)
Nikkei 225
9,187.34 -29.48
(-0.32%)
Forex
USD-INR
87.60 0.00
(0.00%)
EUR-INR
102.16 0.00
(0.00%)
GBP-INR
118.33 0.00
(0.00%)
JPY-INR
0.60 0.00
(0.00%)

EQUITY - MARKET SCREENER

Tribhovandas Bhimji Zaveri Ltd
Industry :  Diamond Cutting / Jewellery
BSE Code
ISIN Demat
Book Value()
534369
INE760L01018
100.0545806
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TBZ
16.53
1236.52
EPS(TTM)
Face Value()
Div & Yield %
11.21
10
1.21
 

Sun Pharma drops as foreign broker downgrades on valuation, execution risks
Aug 26,2025
The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around psoriasis drug Ilumya's heavy Medicare exposure, potential pricing pressures, and limited earnings visibility despite strong initial uptake. It warned that a 10% price cut in Ilumya could erode Sun Pharma’s EPS by 4%.

Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.

The company’s consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.